semaglutide cardiovascular risk 🔴Cardiovascular outcomes with by severity of chronic kidney disease in type 2 diabetes: the FLOW trial⤵️ 🔹Semaglutide significantly reduced the of CV death/MI/stroke regardless of baseline CKD severity in participants Post hoc analysis of SUSTAIN
Description
Use our price checker tool to see how much we can save for you then get started below

Key findings: Nearly 40% of participants had prediabetes

Reddit backs this up

This is due to expanding cardiovascular outcome data